Massachusetts Biotechnology Council

Summary

Partner Kris Bieker was the moderator of the Innovation and Development Panel Discussion entitled, "The Convergence of Medical Devices & Drugs: Advances in Drug Delivery," at the Massachusetts Biotechnology Council in Boston, MA and Waltham, MA.

Speakers

Kristina Bieker
Partner
kbieker@goodwinlaw.com
Boston+1 617 570 1207
/en/people/b/bieker-kristina

Related Content

Big Molecule Watch
September 22, 2023
Update on mRNA Vaccine Patent Litigation
Life Sciences Perspectives
September 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
Big Molecule Watch
September 15, 2023
Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022
Life Sciences Perspectives
September 15, 2023
UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024
Alert
September 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
Big Molecule Watch
September 14, 2023
Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.
Life Sciences Perspectives
September 14, 2023
PropSci Perspectives: Breakthrough Properties
Alert
September 14, 2023
Sunset on (some) Stamp Taxes: HMRC confirms 1.5% charge on issuance and capital raising transfers to depositary receipt and clearance systems will not apply

Summary

Speakers

Kristina Bieker

Related Content

Update on mRNA Vaccine Patent Litigation

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022

UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.

PropSci Perspectives: Breakthrough Properties

Sunset on (some) Stamp Taxes: HMRC confirms 1.5% charge on issuance and capital raising transfers to depositary receipt and clearance systems will not apply

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders

Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines

Bloomberg Intelligence Podcast (Bloomberg)

Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.

Generate:Biomedicines Completes $273 Million Series C

Lauxera Capital Partners Invests €17 Million in BioLamina

Magenta Therapeutics Completes Merger With Dianthus Therapeutics

Andreessen Horowitz-Backed Startup Health IQ Files For Bankruptcy (Forbes)

Life Sciences